Traws Pharma, Inc.
TRAW
$0.83
-$0.01-0.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,103.96% | 1,134.51% | 1,159.29% | 1,184.51% | 0.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,103.96% | 1,134.51% | 1,159.29% | 1,184.51% | 0.44% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,103.96% | 1,134.51% | 1,159.29% | 1,184.51% | 0.44% |
| SG&A Expenses | -33.24% | -30.65% | -11.31% | 12.85% | 13.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.05% | -17.79% | -23.39% | 11.00% | 28.21% |
| Operating Income | 21.22% | 28.24% | 34.49% | 1.85% | -28.53% |
| Income Before Tax | 86.13% | 105.51% | 90.55% | 87.00% | -671.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.13% | 105.51% | 90.55% | 87.00% | -671.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.13% | 105.51% | 90.55% | 87.00% | -671.37% |
| EBIT | 21.22% | 28.24% | 34.49% | 1.85% | -28.53% |
| EBITDA | 21.61% | 28.45% | 34.53% | 1.79% | -28.60% |
| EPS Basic | 92.08% | 102.96% | 85.64% | 84.28% | 38.77% |
| Normalized Basic EPS | 89.51% | 105.86% | 69.83% | 25.04% | 8.71% |
| EPS Diluted | 92.10% | 102.75% | 85.42% | 84.09% | 38.54% |
| Normalized Diluted EPS | 89.56% | 105.49% | 69.38% | 24.53% | 8.22% |
| Average Basic Shares Outstanding | 180.82% | 398.56% | 521.51% | 337.04% | 266.95% |
| Average Diluted Shares Outstanding | 175.26% | 402.57% | 527.78% | 343.51% | 274.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |